Boiron S.A. (BOIRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Boiron S.A. (BOIRF) trades at $31.50 with AI Score 43/100 (Grade C). Boiron S. A. is a leading manufacturer of homeopathic medicines, operating primarily in France and internationally. Market cap: $546.91M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BOIRF: BOIRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BOIRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BOIRF: the 1 perspectives are evenly split.
How is this calculated? →Boiron S.A. (BOIRF) Healthcare & Pipeline Overview
Boiron S.A. specializes in the manufacture and sale of homeopathic medicines, with a strong market presence in Europe and North America, and a diverse product portfolio that addresses various health concerns, from flu symptoms to anxiety disorders.
What Is the Investment Thesis for BOIRF?
Boiron S.A. presents a compelling case for growth in the homeopathic medicine sector, driven by increasing consumer interest in natural and alternative therapies. The company's market capitalization of $546.91M and a P/E ratio of 15.5 indicate a stable financial position, while a gross margin of 73.7% reflects efficient operations. Key growth catalysts include the rising demand for homeopathic remedies, particularly in North America, where awareness of alternative medicine is growing. Additionally, Boiron's established brand reputation and diverse product range position it well to capture market share in an expanding healthcare landscape. However, potential risks include regulatory changes affecting homeopathic products and competition from both traditional pharmaceuticals and other alternative medicine providers. Overall, Boiron's strategic focus on innovation and customer engagement will be crucial for sustaining growth in the coming years.
Based on FMP financials and quantitative analysis
BOIRF Key Highlights
- Market Cap of $546.91M indicates a solid position in the homeopathic sector.
- P/E ratio of 15.5 suggests a stable valuation relative to earnings.
- Profit margin of 3.8% reflects the company's operational efficiency.
- Gross margin of 73.7% exceeds industry averages, indicating strong pricing power.
- Dividend yield of 4.64% provides a return to shareholders amidst growth.
Who Are BOIRF's Competitors?
BOIRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AGYTF Allergy Therapeutics plc | $0.15 | +7.14% | $756.30M | 59 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.64 | -1.26% | $535.91M | 55 |
| CLVSF CellaVision AB (publ) | $14.00 | +0.00% | $333.92M | 52 |
| ELTP Elite Pharmaceuticals, Inc. | $0.36 | +6.41% | $393.14M | 53 |
| GLASF Glass House Brands Inc. | $12.50 | +1.46% | $986.76M | 57 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BOIRF's Key Strengths?
- Strong brand reputation in homeopathy.
- Diverse product offerings across various health categories.
- High gross margin indicating operational efficiency.
- Established distribution channels enhancing market reach.
What Are BOIRF's Weaknesses?
- Limited presence in rapidly growing international markets.
- Dependence on the homeopathic segment, which may face regulatory scrutiny.
- Relatively low profit margins compared to larger pharmaceutical companies.
- Potential challenges in scaling production for new product lines.
What Could Drive BOIRF Stock Higher?
- Expansion into North American markets to capture growing demand for homeopathic products.
- Continued investment in research and development to innovate and diversify product offerings.
- Strengthening of digital marketing strategies to enhance online sales and brand visibility.
- Introduction of new product lines targeting emerging health trends.
- Active engagement with regulatory bodies to navigate potential changes in the homeopathic sector.
What Are the Key Risks for BOIRF?
- Regulatory changes that could impact the sale and marketing of homeopathic products.
- Competition from both traditional pharmaceuticals and other alternative medicine providers.
- Market volatility affecting consumer spending on healthcare products.
- Challenges in scaling production for new product lines amid increasing demand.
What Are the Growth Opportunities for BOIRF?
- Expansion in North America: Boiron S.A. aims to increase its market presence in North America, where the demand for homeopathic products is on the rise. The North American homeopathy market is expected to grow significantly, driven by increasing consumer awareness and preference for natural remedies. By enhancing distribution channels and marketing efforts, Boiron can capture a larger share of this lucrative market within the next five years.
- Product Line Diversification: Boiron plans to expand its product offerings to include new homeopathic remedies and dietary supplements. This diversification strategy targets emerging health trends, such as immunity support and mental wellness, which are gaining traction among consumers. With the global dietary supplement market projected to reach $230 billion by 2027, Boiron's entry into this space could significantly enhance revenue streams.
- Digital Transformation: The company is investing in digital marketing and e-commerce platforms to reach a broader audience. As online sales of health products continue to rise, Boiron's focus on enhancing its digital presence could lead to increased sales and brand loyalty. This initiative aligns with the growing trend of consumers purchasing health products online, especially post-pandemic.
- International Market Penetration: Boiron seeks to penetrate untapped international markets, particularly in Asia and Latin America, where the demand for alternative medicine is growing. By establishing partnerships with local distributors and adapting products to meet regional preferences, Boiron can leverage new revenue opportunities in these emerging markets over the next few years.
- Research and Development: Continued investment in R&D will enable Boiron to innovate and develop new homeopathic formulations. As consumer preferences shift towards personalized medicine, Boiron's commitment to research can position it as a leader in the homeopathic space, potentially increasing market share and enhancing product efficacy.
What Opportunities Does BOIRF Have?
- Growing consumer interest in natural and alternative health products.
- Expansion into emerging markets with increasing demand for homeopathy.
- Digital transformation to enhance online sales and marketing.
- Research and development for innovative product formulations.
What Threats Does BOIRF Face?
- Regulatory changes impacting the homeopathic industry.
- Intense competition from both traditional pharmaceuticals and alternative medicine providers.
- Market volatility affecting consumer spending on healthcare products.
- Potential negative perceptions of homeopathy among some healthcare professionals.
What Are BOIRF's Competitive Advantages?
- Established brand recognition in the homeopathic market.
- Strong product portfolio with a focus on quality and efficacy.
- Commitment to research and development for continuous innovation.
- Diverse distribution channels providing broad market access.
- Expertise in homeopathy, enhancing credibility and trust among consumers.
What Does BOIRF Do?
Founded in 1932 and headquartered in Messimy, France, Boiron S.A. has established itself as a prominent manufacturer and distributor of homeopathic medicines. The company began its journey with a commitment to providing natural remedies and has evolved into a leader in the homeopathy sector, offering both proprietary and non-proprietary products. Boiron's extensive range includes well-known brands such as Oscillococcinum, which is used for flu-like symptoms, and Sédatif PC, aimed at alleviating anxiety and sleep disorders. The company also produces a variety of herbal medicines and dietary supplements, catering to diverse health needs. Boiron's distribution network spans pharmacies, grocery stores, health food outlets, and online platforms, enabling it to reach a broad customer base across France, Europe, North America, and beyond. With a workforce of approximately 2,469 employees, Boiron continues to innovate and expand its product offerings, maintaining a strong commitment to the principles of homeopathy and natural health.
What Products and Services Does BOIRF Offer?
- Manufacture and sell homeopathic medicines globally.
- Offer a wide range of branded homeopathic products for various health issues.
- Provide dietary supplements and herbal medicines.
- Develop medical devices, including COVID self-tests.
- Distribute products through pharmacies, health food stores, and online retail.
- Focus on innovation and quality in homeopathic formulations.
How Does BOIRF Make Money?
- Generate revenue through the sale of homeopathic and herbal medicines.
- Leverage a diverse product portfolio to cater to various health needs.
- Utilize a multi-channel distribution strategy to reach consumers effectively.
- Invest in research and development to innovate and expand product offerings.
- Engage in marketing initiatives to enhance brand awareness and customer loyalty.
What Industry Does BOIRF Operate In?
The drug manufacturing industry, particularly the specialty and generic segment, is witnessing significant growth, driven by increasing consumer preference for natural and homeopathic treatments. The global homeopathy market is projected to expand at a CAGR of approximately 15% over the next five years, fueled by rising awareness of alternative medicine and the growing prevalence of chronic diseases. Boiron S.A. is well-positioned within this landscape, leveraging its established brand and diverse product offerings to compete against both traditional pharmaceutical companies and other homeopathic providers. The competitive landscape includes peers such as AGYTF, BJTRF, CLVSF, ELTP, and GLASF, all of which are vying for market share in this evolving sector.
Who Are BOIRF's Key Customers?
- Pharmacies and pharmacy chains across Europe and North America.
- Health food stores and grocery outlets.
- Online consumers seeking natural health products.
- Healthcare professionals recommending homeopathic remedies.
- Parents looking for safe treatments for children.
FY2026 estForward Outlook
Wall Street analysts project Boiron S.A. revenue of about $508.4M for fiscal 2026, with EPS near $2.01.
F-Score 6/9Financial Health
Boiron S.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.14 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 9%Key Financial Metrics
Return on equity for Boiron S.A. stands at 8.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.4%, showing how much profit it generates from its asset base. BOIRF trades at a trailing price-to-earnings ratio of 15.46, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.7%, the inverse of the P/E and a quick read on earnings relative to price.
Boiron S.A. (BOIRF) Valuation Context
Valued at $546.91M, BOIRF is classified as a small-cap stock. Relative to its peer group, BOIRF's quantitative score of 43/100 is below the peer average of 55/100.
BOIRF Revenue & Earnings Trend
In Q2 2025, BOIRF generated $245.6M in top-line revenue, marking a sequential decrease of 5.2%. The company recorded net income of $11.4M, with diluted EPS of $0.65. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.
Company Profile
Boiron S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Messimy, FR. The company is led by CEO Thierry Boiron. BOIRF has traded publicly since 1996.
BOIRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand reputation in homeopathy.
- Diverse product offerings across various health categories.
- High gross margin indicating operational efficiency.
- Established distribution channels enhancing market reach.
Bear Case
- Limited presence in rapidly growing international markets.
- Dependence on the homeopathic segment, which may face regulatory scrutiny.
- Relatively low profit margins compared to larger pharmaceutical companies.
- Potential challenges in scaling production for new product lines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $246M | $11M | $0.65 |
| Q4 2024 | $259M | $8M | $0.46 |
| Q2 2024 | $228M | $3M | $0.19 |
Based on FMP financials and quantitative analysis
BOIRF Latest News
No recent news available for BOIRF.
BOIRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BOIRF.
Price Targets
Wall Street price target analysis for BOIRF.
BOIRF MoonshotScore
What does this score mean?
The MoonshotScore rates BOIRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thierry Boiron
CEO
Thierry Boiron has been instrumental in leading Boiron S.A. since its inception. With a strong background in homeopathy and healthcare management, he has dedicated his career to promoting natural remedies. Under his leadership, the company has expanded its product offerings and strengthened its market position in the homeopathic sector.
Track Record: Thierry has successfully guided Boiron through various market challenges, enhancing brand recognition and driving international expansion. His strategic focus on innovation has resulted in the introduction of several new products that align with consumer health trends.
BOIRF OTC Market Information
The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ. These stocks may have less stringent reporting requirements and can be less liquid, often resulting in wider bid-ask spreads. Investors should be aware of the potential for lower trading volumes and increased volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks listed on major exchanges, which can affect trading.
- Increased volatility due to limited analyst coverage and market interest.
- Potential for less transparency in financial reporting and disclosures.
- Regulatory risks associated with the homeopathic sector.
- Review available financial reports and earnings releases.
- Assess the company's competitive positioning and market trends.
- Monitor regulatory developments affecting homeopathic products.
- Evaluate management's track record and strategic vision.
- Investigate market sentiment and analyst opinions.
- Established brand presence in the homeopathic market since 1932.
- Comprehensive product portfolio with a focus on quality.
- Positive consumer feedback and brand loyalty in target markets.
BOIRF Healthcare Stock FAQ
What does Boiron S.A. do?
Boiron S.A. specializes in the manufacture and sale of homeopathic medicines, dietary supplements, and herbal products. The company offers a diverse range of branded homeopathic remedies for various health concerns, including flu symptoms, anxiety, and skin conditions, primarily targeting markets in Europe and North America.
What do analysts say about BOIRF stock?
Analysts generally view Boiron S.A. as a stable player in the homeopathic sector, with a focus on natural health products. Key valuation metrics, such as a P/E ratio of 15.5 and a gross margin of 73.7%, indicate solid financial health. Growth considerations include the rising demand for homeopathic remedies and the company's ongoing innovation efforts.
What are the main risks for BOIRF?
Boiron S.A. faces several risks, including potential regulatory changes that could impact the homeopathic market and ongoing competition from both traditional pharmaceuticals and alternative medicine providers. Additionally, market volatility may affect consumer spending on healthcare products, and challenges in scaling production for new product lines could hinder growth.
What are the key factors to evaluate for BOIRF?
Boiron S.A. (BOIRF) holds an AI score of 43/100 (low). P/E: 15.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does BOIRF data refresh on this page?
BOIRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BOIRF's recent stock price performance?
Boiron S.A. (BOIRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation in homeopathy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BOIRF overvalued or undervalued right now?
Boiron S.A. (BOIRF) trades at 15.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BOIRF?
Before investing in Boiron S.A. (BOIRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company reports and market analysis. Financial metrics are subject to change based on market conditions.